Joshua Fitch, Senior Editor

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

A Chinese study found that menstrual blood HPV testing had a comparable diagnostic accuracy to clinician-collected cervical samples in detecting CIN2+ and CIN3+.

A new ACOG Committee Statement outlines how immigration status affects health outcomes and calls for enforcement-free health care settings.

ACOG continues to support maternal immunization against COVID-19, flu, and RSV amid growing public questions about vaccine safety during pregnancy.

Take a look back at any of our expert video interviews you may have missed from January 2026.

Take a quick look at everything you may have missed in January, from our latest video interviews to new clinical trial data to a FAQ on cervical cancer.

Trial shows higher sensitivity with AI-supported breast cancer screening.

Federal guidance now designates primary hrHPV testing every 5 years as the preferred cervical cancer screening method for most average-risk women aged 30 to 65 years and adds patient self-collection as an acceptable option.

Universal prenatal syphilis screening legislation in Michigan was followed by substantial increases in early third-trimester testing among Medicaid enrollees.

United States labor induction rates have expanded to 37 and 38 weeks despite a lack of randomized evidence supporting non–medically indicated induction before 39 weeks.

The pause request comes as the administration considers whether to keep current federal rules in place that allow for remote access to mifepristone.

A new AHA scientific statement outlines how earlier prevention, rapid diagnosis and timely treatment can reduce the risks of maternal stroke during pregnancy and postpartum.

New national data show major declines in RA mortality among older women, alongside enduring racial and geographic inequities.

Menopause was associated with increased anxiety, depression, sleep problems and reductions in grey matter in key brain regions.

New FDA guidance and AACR-bound data highlight Aviva Bio’s progress in developing a differentiated testosterone therapy aimed at reducing breast cancer risk in women.

The AAP'S 2026 schedule has been endorsed by 12 medical and health organizations, including the American College of Nurse Midwives and the American College of Obstetricians and Gynecologists.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

In patients with diet-controlled gestational diabetes, continuing pregnancy beyond 39 weeks was associated with increasing maternal and neonatal risks.

A large cohort study found that prenatal exposure to acid-suppressive medications was not associated with neuropsychiatric disorders in children.

A single subcutaneous dose of RE104 produced rapid and durable improvements in postpartum depression, supporting advancement into phase 3 development.

A nationwide Norwegian cohort study suggests that prenatal factors, including fetal growth and maternal diabetes, may influence the risk of developing multiple sclerosis in adulthood.

The extended approval and contracpetive efficacy during use from 3 to 5 years was based on a multicenter, single-arm, open-label study (NCT04626596) conducted in the United States.

A large systematic review and meta-analysis found no evidence that paracetamol use during pregnancy increases the risk of autism, ADHD, or intellectual disability in children.

A phase 3 trial of oral brexanolone for postpartum depression will continue unchanged following a favorable DSMB safety review.

A population-based study links minimum wage increases to improved maternal cardiovascular health during pregnancy.

New data suggest that diabetes risk after menopause is driven by cardiometabolic factors rather than when or how menopause occurs.

A large California cohort study shows that aggregating Asian American and Pacific Islander populations can obscure substantial differences in hypertensive disorder risk during pregnancy.

New HRSA guidelines strengthen cervical cancer prevention by adding self-collected hrHPV testing and clarifying no-cost coverage for additional diagnostic services.

Analysis of internal FDA records reveals that mifepristone’s REMS program was shaped by repeated evidence-based safety reviews.

Screen-guided care using the PreTRM blood test reduced preterm birth–related complications and NICU use.